CD117+ cells in the circulation are predictive of advanced prostate cancer

Kerr, Bethany A.; Miocinovic, Ranko; Smith, Arthur L.; West, Xiaoxia Z.; Watts, Katherine E.; Alzayed, Amanda W.; Klink, Joseph C.; Mir, M.C.; Sturey, Tiffany; Hansel, Donna E.; Heston, Warren D.W.; Stephenson, Andrew J.; Klein, Eric A.; Byzova, Tatiana V.

doi:10.18632/oncotarget.2796

Cited by 47 publications

(39 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to CXCL12, stem cell factor (SCF), another osteoblast-derived factor that regulates HSC function [47], may promote prostate cancer bone metastasis. Indeed, circulating tumor cells [48] and bone metastatic samples [49] obtained from prostate cancer patients express a receptor for SCF, c-Kit or CD117, which is highly expressed in advanced prostate cancer. The effects of cabozantinib (XL184), a small molecule inhibitor which targets c-Kit, were evaluated in a phase II randomized discontinuation trial in men with castration-resistant bone metastatic prostate cancer [50].…”

Section: Mechanisms Of Prostate Cancer Bone Metastasismentioning

confidence: 99%

Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis

2017

View full text Add to dashboard Cite

Bone is the most common site of prostate cancer metastasis. Once prostate cancer cells metastasize to bone, the mortality rate of prostate cancer patients increases significantly. Furthermore, bone metastases produce multiple skeletal complications, including bone pain that impairs the patients' quality of life. Effective therapies for bone metastatic disease are underdeveloped with most current therapies being primarily palliative with modest survival benefit. Although the exact mechanisms through which prostate cancer metastasizes to bone are unclear, growing evidence suggests that the bone marrow microenvironment, particularly its hematopoietic activity, is a significant mediator of prostate cancer bone tropism. Moreover, the bone microenvironment may regulate metastatic prostate cancer cells between dormant and proliferative states. In this review, we discuss (1) how prostate cancer cells interact with the bone microenvironment to establish bone metastases and (2) current and future potential treatments for prostate cancer patients with bone metastases.

show abstract

Section: Mechanisms Of Prostate Cancer Bone Metastasismentioning

confidence: 99%

Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis

2017

View full text Add to dashboard Cite

show abstract

“…The FACS analysis has assessed not only the mesenchymal origin but also the non-malignancy of our clone. In particular, the negative results obtained analyzing the main surface markers expressed within the majority of solid tumors (CD133, CD117, CD34 and CD271) (23)(24)(25)(26)(27), together with the cell inability to form colonies in soft agar (28), confirmed that no malignant transformation occurred during cloning of PDL cells. In order to assess its potential and capability to differentiate into different lineages, we induced the clonal CD44+ PDL line toward adipogenic and osteogenic phenotypes.…”

Section: Discussionmentioning

confidence: 91%

The effect of strontium chloride on human periodontal ligament stem cells

Romagnoli

Zonefrati

Galli

et al. 2017

ccmbm

View full text Add to dashboard Cite

SummaryThe complete repair of periodontal structures remains an exciting challenge that prompts researchers to develop new treatments to restore the periodontium. Recent research has suggested strontium ion to be an attractive candidate to improve osteogenic activity. In this study, we have isolated a clonal finite cell line derived from human periodontal ligament (PDL) in order to assess whether and in which way different doses of SrCl2 (from 0.5 to 500 μg/ml) can influence both the proliferation and the mineralization process, for future application in oral diseases. PDL cells were cloned by dilution plating technique and characterized by FACS. Cell proliferation analysis and mineralization were performed by [ 3 H]-thymidine incorporation and spectrofluorometric assay. Results have evidenced that the higher SrCl2 concentrations tested, from 25 to 500 μg/ml, have increased the proliferation activity after only 24 h of treatment. Interestingly, the same higher concentrations have decreased the mineralization, which was conversely increased by the lower ones, from 0.5 to 10 μg/ml. Our findings suggest the possible use of SrCl2 in appropriate delivery systems that release, at different time points, the specific dose, depending on the biological response that we want to induce on periodontal ligament stem cells, providing a more efficient periodontal regeneration.

show abstract

“…Furthermore, inhomogeneous use of hormones in this study could confound the findings. Of note, some molecular markers such as CD117+ cell levels and miRNAs (miR-103, 125b, and 222) expression have been proposed for the prediction of biochemical failure for patients after RP and decide timing of salvage treatment [32, 33]. The prospective multi-center study will be needed to confirm the results.…”

Section: Discussionmentioning

confidence: 99%